1
|
Matharoo-Ball B, Diop M, Kozlakidis Z. Harmonizing the COVID-19 sample biobanks: Barriers and opportunities for standards, best practices and networks. BIOSAFETY AND HEALTH 2022; 4:280-282. [PMID: 35844964 PMCID: PMC9270233 DOI: 10.1016/j.bsheal.2022.06.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/05/2022] [Revised: 06/27/2022] [Accepted: 06/30/2022] [Indexed: 11/17/2022] Open
Abstract
The coronavirus disease 2019 (COVID-19) pandemic has highlighted the practice of infectious diseases biobanking, as well as existing challenges and opportunities. Thus, the future of infectious diseases biobanking in the post-pandemic era, shall not be an "entry-level version" of its counterpart in non-communicable diseases and large population cohorts, but incorporate the lessons learned. Biobanks constitute a critical research infrastructure supported by harmonized practices through the implementation of international standards, and perceived within the broader scope of healthcare's intersection with research. This perspective paper considers the barriers in biobanking and standardization of practices, as well as the emerging opportunities in the field.
Collapse
Affiliation(s)
| | | | - Zisis Kozlakidis
- International Agency for Research on Cancer, World Health Organization, 69372 Lyon CEDEX 08, France
| |
Collapse
|
2
|
Jaffal L, Mrad Z, Ibrahim M, Salami A, Audo I, Zeitz C, El Shamieh S. The research output of rod-cone dystrophy genetics. Orphanet J Rare Dis 2022; 17:175. [PMID: 35461258 PMCID: PMC9034540 DOI: 10.1186/s13023-022-02318-5] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/15/2021] [Accepted: 04/09/2022] [Indexed: 11/10/2022] Open
Abstract
Non-syndromic rod-cone dystrophy (RCD) is the most common condition in inherited retinal diseases. The aim of this study was to evaluate the research output and productivity related to RCD genetics per countries as classified by the human development index (HDI), by analyzing publication frequency and citations, the choice of journals and publishers, since 2000 to date. We have also analyzed the use of next-generation sequencing (NGS) in publications originating from countries with different HDIs. One thousand four hundred articles focusing on non-syndromic RCD were downloaded and analyzed. Citations and published articles were adjusted per one million individuals. The research output is significantly higher in very high HDI countries (86% of the total publications and 95% of the citations) than countries with lower HDIs in all aspects. High and medium HDI countries published together 13.6% of the total articles worldwide and received 4.6% of the citations. On the publication level, the USA (26%), United Kingdom (10%), and Japan (7%) were the top 3 among very high HDI countries, while China (6%) and India (2%) ranked first in high and medium HDI countries respectively. On the citation level, similar profiles were found. Following adjustment for population size, Switzerland (~14%), Jordan (~ 1%) and Morocco (<0.2%) showed the highest rates of publications in very high, high and medium HDI countries respectively. Very high HDI countries published 71% of their papers in first quartile journals (first quartile in Scimago journal rank; Q1), and 23% in Q2 journals. High and medium HDI countries showed a similar profile in quartiles with ~ 40% of their papers published in Q1 journals and ~ 30% in Q2 journals. The first publication using NGS was issued in 2009 in very high HDI countries, while it appeared in 2012 in high HDI countries, and in 2017 in medium HDI countries, with a respective lag of 3 to 8 years compared to very high HDI countries. A profound gap exists between very high HDI countries and the rest of the world. To fill it in, we propose implementing NGS, supporting international collaborations, building capacities and infrastructures, improving accessibility of patients to services, and increasing national and international funding.
Collapse
Affiliation(s)
- Lama Jaffal
- Rammal Hassan Rammal Research Laboratory, PhyToxE Research Group, Faculty of Sciences, Lebanese University, Nabatieh, Lebanon.,Department of Biological and Chemical Sciences, School of Arts and Sciences, Lebanese International University, Beirut, Lebanon
| | - Zamzam Mrad
- Rammal Hassan Rammal Research Laboratory, PhyToxE Research Group, Faculty of Sciences, Lebanese University, Nabatieh, Lebanon
| | - Mariam Ibrahim
- Rammal Hassan Rammal Research Laboratory, PhyToxE Research Group, Faculty of Sciences, Lebanese University, Nabatieh, Lebanon
| | - Ali Salami
- Department of Mathematics, Faculty of Sciences, Lebanese University, Nabatieh, Lebanon
| | - Isabelle Audo
- Sorbonne Université, INSERM, CNRS, Institut de La Vision, Paris, France.,CHNO Des Quinze-Vingts, INSERM-DGOS CIC1423, Paris, France.,University College London Institute of Ophthalmology, London, UK
| | - Christina Zeitz
- Sorbonne Université, INSERM, CNRS, Institut de La Vision, Paris, France
| | - Said El Shamieh
- Department of Medical Laboratory Technology, Faculty of Health Sciences, Beirut Arab University, Beirut, Lebanon.
| |
Collapse
|
3
|
Dwianingsih EK, Yunus J, Lazuardi L, Wahdi AE, Rhamadianti AF, Linda F, Hariyanto S, Fachiroh J. Building a Biobank Network for Health Research in Indonesia. Open Access Maced J Med Sci 2022. [DOI: 10.3889/oamjms.2022.8875] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022] Open
Abstract
BACKGROUND: Biobanks play an essential role in the development of personalized medicine since they collect large numbers of high-quality biomaterials corresponding to clinical data. Despite its extensive population diversity, research institutions in Indonesia have indicated less awareness regarding biobanking for research practices.
AIM: The journey to harmonize the knowledge and understanding of biobanks for health research and the development of the network in Indonesia has been summarized in this article.
METHODS: To build a national biobank network, in 2015 the Faculty of Medicine, Public Health and Nursing, UGM held the first national biobank network meeting in Indonesia. Follow-up meetings were then held to identify challenges and constraints faced by the network. Five annual national workshops (2015–2019) have been held.
RESULTS: Four working groups (WG) were formed to effectively coordinate the network, addressing the infrastructure and Laboratory Information Management System (WG 1), SOP and Best Practices (WG 2), Training and Education and Legal (WG 3), and Ethical and Social Issues (WG 4).
CONCLUSION: The formation of a national biobank network in Indonesia is based on the hope for multi-institutional collaboration to mainly foster the development of biobanks for health research with best available practices and provide a central hub of coordination.
Collapse
|
4
|
Beusink M, Broeks A, van Kemenade FJ, Lam KH, Schmidt MK, Rebers S. Barriers and Facilitators for Implementing a National Guideline to Foster the Responsible Use of Residual Biospecimens and Data in Health Research. Biopreserv Biobank 2021; 20:67-74. [PMID: 34582256 DOI: 10.1089/bio.2020.0164] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Residual biospecimens that are stored in hospitals' diagnostic specimen archives can be used for scientific research under strict legal and ethical regulations. In the Netherlands, a Code of Conduct governs responsible secondary use of residual biospecimens. However, implementation of this Code seems to be challenging. This study aims to explore the most important factors that facilitate or hinder the implementation of the Code. In addition, it investigates what is needed to further foster the responsible use of residual biospecimens. A mixed-methods design was used. Questionnaires were sent out to pathologists, patient information centers, physicians, researchers, data protection officers (DPOs), members of research ethics committees, and members of the boards of directors of all hospitals in the Netherlands (81 hospitals). To further investigate the barriers and facilitators, interviews were conducted with pathologists, patient information centers, physician-researchers, DPOs, review boards, research coordinators, and quality managers of pathology departments. In total, 246 respondents filled out the questionnaire and 36 interviews were conducted. Major barriers for implementing were a lack of resources (time, money), a lack of attention for responsible use, and a lack of practical knowledge (knowing what to do, where to go with questions). In contrast, the perception that implementing the Code was necessary, either by the respondent or by colleagues, was considered "a driver" for implementation. Practical instruments such as checklists and roadmaps were considered necessary to foster implementation; however, the creation of such instruments was hindered by a lack of clear-cut answers regarding legal aspects. Therefore, more clarity and harmonization on how to interpret both the Code and legislation regarding secondary use were considered necessary.
Collapse
Affiliation(s)
- Miriam Beusink
- Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
| | - Annegien Broeks
- Core Facility-Molecular Pathology and Biobanking, The Netherlands Cancer Institute, Amsterdam, The Netherlands
| | | | - King H Lam
- Pathology Department, Erasmus MC, Rotterdam, The Netherlands
| | - Marjanka K Schmidt
- Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
| | - Susanne Rebers
- Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
| |
Collapse
|
5
|
Gramatiuk SM, Bagmut IY, Sheremet MI, Sargsyan K, Yushko AM, Filipchenko SM, Maksymyuk VV, Tarabanchuk VV, Moroz PV, Popovich AI. Pediatric biobanks and parents of disabled children associations opinions on establishing children repositories in developing countries. J Med Life 2021; 14:50-55. [PMID: 33767785 PMCID: PMC7982269 DOI: 10.25122/jml-2020-0106] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
Pediatric biobanks are an indispensable resource for the research needed to bring advances in personalized medicine into pediatric medical care. It is unclear how or when these advances in medical care may reach children, but it is unlikely that research in adults will be adequate. We conducted the screening for a hypothetic problem in various European and American pediatric biobanks based on online surveys through e-mail distribution based on the Biobank Economic Modeling Tool (BEMT) questionnaire model. Participants in the survey had work experience in biobanking for at least 3 years or more. Contact information about the survey participants was confirmed on the social networks profiles (LinkedIn), as well as on generally available websites. First, we tried creating a model which can show the pediatric preclinical and basic clinical phase relationship and demonstrate how pediatric biobanking is linked to this process. Furthermore, we tried to look for new trends, and the final goal is to put the acquired knowledge into practice, so medical experts and patients could gain usable benefit from it. We concluded that leading positions must take into account ethical and legal aspects when considering the decision to include children in the biobank collection. However, communication with parents and children is essential. The biobank characteristics influence the biobank's motives to include children in the consent procedure. Moreover, the motives to include children influence how the children are involved in the consent procedure and the extent to which children are able to make voluntary decisions as part of the consent procedure.
Collapse
Affiliation(s)
| | | | | | | | - Alla Mironovna Yushko
- Ukraine Association of Biobank, Institute of Cellular Biorehabilitation, Kharkiv, Ukraine.,Yaroslav Mudryi National Law University, Kharkiv, Ukraine
| | | | | | | | | | - Andriy Ivanovich Popovich
- Department of Pathology (Pathology and Forensic Medicine), Bukovinian State Medical University, Chernivtsi, Ukraine
| |
Collapse
|
6
|
Devriendt T, Shabani M, Borry P. Data Sharing in Biomedical Sciences: A Systematic Review of Incentives. Biopreserv Biobank 2021; 19:219-227. [PMID: 33926229 DOI: 10.1089/bio.2020.0037] [Citation(s) in RCA: 13] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Background: The lack of incentives has been described as the rate-limiting step for data sharing. Currently, the evaluation of scientific productivity by academic institutions and funders has been heavily reliant upon the number of publications and citations, raising questions about the adequacy of such mechanisms to reward data generation and sharing. This article provides a systematic review of the current and proposed incentive mechanisms for researchers in biomedical sciences and discusses their strengths and weaknesses. Methods: PubMed, Web of Science, and Google Scholar were queried for original research articles, editorials, and opinion articles on incentives for data sharing. Articles were included if they discussed incentive mechanisms for data sharing, were applicable to biomedical sciences, and were written in English. Results: Although coauthorship in return for the sharing of data is common, this might be incompatible with authorship guidelines and raise concerns over the ability of secondary analysts to contest the proposed research methods or conclusions that are drawn. Data publication, citation, and altmetrics have been proposed as alternative routes to credit data generators, which could address these disadvantages. Their primary downsides are that they are not well-established, it is difficult to acquire evidence to support their implementation, and that they could be gamed or give rise to novel forms of research misconduct. Conclusions: Alternative recognition mechanisms need to be more commonly used to generate evidence on their power to stimulate data sharing, and to assess where they fall short. There is ample discussion in policy documents on alternative crediting systems to work toward Open Science, which indicates that that there is an interest in working out more elaborate metascience programs.
Collapse
Affiliation(s)
- Thijs Devriendt
- Department of Public Health and Primary Care, Centre for Biomedical Ethics and Law, KU Leuven, Leuven, Belgium
| | - Mahsa Shabani
- Department of Public Health and Primary Care, Centre for Biomedical Ethics and Law, KU Leuven, Leuven, Belgium.,Metamedica, Faculty of Law and Criminology, Ghent University, Gent, Belgium
| | - Pascal Borry
- Department of Public Health and Primary Care, Centre for Biomedical Ethics and Law, KU Leuven, Leuven, Belgium
| |
Collapse
|
7
|
Colledge F, Passweg J, Elger B. Obstacles to Widening Biosample Research. SCIENCE AND ENGINEERING ETHICS 2019; 25:113-128. [PMID: 29063372 DOI: 10.1007/s11948-017-9985-0] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/16/2017] [Accepted: 10/12/2017] [Indexed: 06/07/2023]
Abstract
Switzerland has an excellent culture of medical research and is a melting pot for medical experts with international expertise. Nevertheless, as in other countries, the resources available to medical researchers are not being fully used. Biological samples, which enable a host of medical research studies to be carried out without invasive methods involving patients, are frequently left unused or forgotten. The aim of this study is to examine the experiences of biobank stakeholders regarding the use or underuse of biosamples, in order to develop paths to optimize biosample research. Interviews were carried out with 36 biobank stakeholders in Switzerland concerning their experiences with biosample use, and the possible obstacles at each stage of the process. Interviews revealed that standard operating procedures were the most frequently cited obstacle, although these were not judged to be severe hindrances. Despite a stated desire to develop biosample research, skepticism of sharing networks and wariness of new partnerships were strong themes. Biobanking still functions as an emerging field, in which exchange practices have yet to be established at the national and international levels. Sample exchange continues to function largely based on personal contacts; while this is an inherent feature of competitive medical research, opportunities for large-scale studies may be lost due to excessive caution.
Collapse
Affiliation(s)
- Flora Colledge
- Department of Sport, Exercise and Health, University of Basel, Birsstrasse 320b, 4052, Basel, Switzerland.
| | - Jakob Passweg
- Hematology Clinic, University Hospital of Basel, Basel, Switzerland
| | - Bernice Elger
- Institute for Biomedical Ethics, University of Basel, Bernoullistrasse 28, 4056, Basel, Switzerland.
| |
Collapse
|
8
|
Newborn dried blood spot samples in Denmark: the hidden figures of secondary use and research participation. Eur J Hum Genet 2018; 27:203-210. [PMID: 30287898 PMCID: PMC6336790 DOI: 10.1038/s41431-018-0276-2] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/06/2018] [Revised: 08/11/2018] [Accepted: 08/19/2018] [Indexed: 01/30/2023] Open
Abstract
Each year millions of newborns are part of a newborn disease-screening program in which, after initial screening, the newborn dried blood spot (NDBS) samples can be stored and used as a population-based research resource. However, very little knowledge exists about how these samples are used for secondary purposes. Our objective is to estimate and describe the usage of a NDBS-based national population biobank for secondary research purposes. We therefore conducted a scoping study with a literature search for all published articles using samples from the Danish Newborn Screening Biobank. Our main inclusion criteria were that the articles had to have actively used and analyzed one or more of the Danish NDBS samples for a purpose beyond the primary screening. Our search led to a final 104 articles, which were coded for three main purposes: (1) how many samples were used in each article, (2) the field of their research, and (3) information on consent and ethics approval as research. From our analysis, we present two main findings: an estimated use of up to 37.5% of all samples in the newborn screening biobank have been part of published research, and a shift in the research areas from methodological and metabolic studies to studies concerning mental illness. This paper provides new insights into the use of a national biobank, and we hope that the results will contribute to the discussions on the use of biological samples for research purposes, and also inspire a greater transparency in the future use of NDBS samples.
Collapse
|
9
|
Holub P, Kohlmayer F, Prasser F, Mayrhofer MT, Schlünder I, Martin GM, Casati S, Koumakis L, Wutte A, Kozera Ł, Strapagiel D, Anton G, Zanetti G, Sezerman OU, Mendy M, Valík D, Lavitrano M, Dagher G, Zatloukal K, van Ommen GB, Litton JE. Enhancing Reuse of Data and Biological Material in Medical Research: From FAIR to FAIR-Health. Biopreserv Biobank 2018; 16:97-105. [PMID: 29359962 PMCID: PMC5906729 DOI: 10.1089/bio.2017.0110] [Citation(s) in RCA: 48] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/16/2023] Open
Abstract
The known challenge of underutilization of data and biological material from biorepositories as potential resources for medical research has been the focus of discussion for over a decade. Recently developed guidelines for improved data availability and reusability-entitled FAIR Principles (Findability, Accessibility, Interoperability, and Reusability)-are likely to address only parts of the problem. In this article, we argue that biological material and data should be viewed as a unified resource. This approach would facilitate access to complete provenance information, which is a prerequisite for reproducibility and meaningful integration of the data. A unified view also allows for optimization of long-term storage strategies, as demonstrated in the case of biobanks. We propose an extension of the FAIR Principles to include the following additional components: (1) quality aspects related to research reproducibility and meaningful reuse of the data, (2) incentives to stimulate effective enrichment of data sets and biological material collections and its reuse on all levels, and (3) privacy-respecting approaches for working with the human material and data. These FAIR-Health principles should then be applied to both the biological material and data. We also propose the development of common guidelines for cloud architectures, due to the unprecedented growth of volume and breadth of medical data generation, as well as the associated need to process the data efficiently.
Collapse
Affiliation(s)
| | | | | | | | | | | | - Sara Casati
- BBMRI.it and Universita degli Studi di Milano-Bicocca, Milano, Italy
| | - Lefteris Koumakis
- BBMRI.gr and Foundation for Research and Technology-Hellas, Heraklion, Greece
| | | | - Łukasz Kozera
- BBMRI.pl and Wroclaw Research Centre EIT+, Wroclaw, Poland
| | | | | | | | | | - Maimuna Mendy
- BBMRI.IARC and International Agency for Research on Cancer, Lyon, France
| | - Dalibor Valík
- BBMRI.cz and Masaryk Memorial Cancer Institute, Brno, Czech Republic
| | | | | | | | | | | |
Collapse
|
10
|
Seiler CY, Eschbacher J, Bowser R, LaBaer J. Sustainability in a Hospital-Based Biobank and University-Based DNA Biorepository: Strategic Roadmaps. Biopreserv Biobank 2016; 13:401-9. [PMID: 26697909 DOI: 10.1089/bio.2015.0076] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022] Open
Abstract
Sustainability in the biobanking community has recently become an important and oft-discussed issue as biorepositories struggle to balance limited external funding and complex cost recovery models with high operating costs and the desire to provide the highest quality materials and services to the research community. A multi-faceted view of biobanking sustainability requires consideration of operational and social sustainability in addition to the historical focus exclusively on financial sustainability. Planning and implementing this three pillar model creates a well-rounded biorepository that meets the needs of all the major stakeholders: the funders, the patients/depositors, and the researcher recipients. Often the creation of a detailed business plan is the first step to develop goals and objectives that lead down a path towards sustainability. The definition of sustainability and the complexity of a sustainable business plan may differ for each biorepository. The DNASU Plasmid Repository at Arizona State University stores and distributes DNA plasmids to researchers worldwide, and the Biobank Core Facility at St. Joseph's Hospital and Barrow Neurological Institute consents patients and collects, stores, and distributes human tissue and blood samples. We will discuss these two biorepositories, their similar and different approaches to sustainability and business planning, their challenges in creating and implementing their sustainability plan, and their responses to some of these challenges. From these experiences, the biobanks share lessons learned about planning for sustainability that are applicable to all biorepositories.
Collapse
Affiliation(s)
- Catherine Y Seiler
- 1 The Biobank Core Facility at St. Joseph's Hospital and Barrow Neurological Institute , Phoenix, Arizona
| | - Jennifer Eschbacher
- 1 The Biobank Core Facility at St. Joseph's Hospital and Barrow Neurological Institute , Phoenix, Arizona
| | - Robert Bowser
- 2 Divisions of Neurology and Neurobiology, Barrow Neurological Institute , Phoenix, Arizona
| | - Joshua LaBaer
- 3 DNASU Plasmid Repository, Virginia G. Piper Center for Personalized Diagnostics, Biodesign Institute, Arizona State University , Tempe, Arizona
| |
Collapse
|
11
|
Benson EE, Harding K, Mackenzie-dodds J. A new quality management perspective for biodiversity conservation and research: Investigating Biospecimen Reporting for Improved Study Quality (BRISQ) and the Standard PRE-analytical Code (SPREC) using Natural History Museum and culture collections as case studies. SYST BIODIVERS 2016. [DOI: 10.1080/14772000.2016.1201167] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
Affiliation(s)
- Erica E. Benson
- Damar Research Scientists, Damar, Drum Road, Cuparmuir, Fife, Scotland KY15 5RJ, UK
| | - Keith Harding
- Damar Research Scientists, Damar, Drum Road, Cuparmuir, Fife, Scotland KY15 5RJ, UK
| | - Jacqueline Mackenzie-dodds
- Molecular Collections, Department of Life Sciences, Natural History Museum, Cromwell Road, London SW7 5BD, UK
| |
Collapse
|
12
|
Edwards KA, Terry SF, Gold D, Horn EJ, Schwartz M, Stuart M, Vernon SD. Realizing Our Potential in Biobanking: Disease Advocacy Organizations Enliven Translational Research. Biopreserv Biobank 2016; 14:314-8. [PMID: 27058463 DOI: 10.1089/bio.2015.0053] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Biobanks are increasingly powerful tools used in translational research, and disease advocacy organizations (DAOs) are making their presence known as research drivers and partners. We examined DAO approaches to biobanking to inform how the enterprise of biobanking can grow and become even more impactful in human health. In this commentary, we outline overarching approaches from successful DAO biobanks. These lessons learned suggest principles that can create a more participant-centric approach and illustrate the key roles DAOs can play as partners in research initiatives. DAO approaches to biobanking for translational research include the following: be outcome driven; forge alliances that are unexpected-build bridges to enhance translation; come ready for success; be nimble, flexible, and adaptable; and remember that people matter. Each of these principles led to particular practices that have increased the translational impact of biobank collections. The research practices discussed can inform partnerships in all sectors going forward.
Collapse
Affiliation(s)
- Kelly A Edwards
- 1 Department of Bioethics and Humanities, University of Washington School of Medicine , Seattle, Washington
| | - Sharon F Terry
- 2 Genetic Alliance, Inc. , Washington, District of Columbia.,3 PXE International, Washington, District of Columbia
| | - Dana Gold
- 4 University of Washington , Seattle, Washington
| | | | - Mary Schwartz
- 6 Pachyonychia Congenita Project, Salt Lake City, Utah
| | - Molly Stuart
- 7 Strategic Change Consultant, Davis, California
| | | |
Collapse
|
13
|
Verlinden M, Nys H, Ectors N, Huys I. Qualitative study on custodianship of human biological material and data stored in biobanks. BMC Med Ethics 2016; 17:15. [PMID: 26926004 PMCID: PMC4772467 DOI: 10.1186/s12910-016-0098-0] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/24/2015] [Accepted: 02/22/2016] [Indexed: 12/16/2022] Open
Abstract
BACKGROUND Balancing the rights and obligations of custodians and applicants in relation to access to biobanks is of utmost importance to guarantee trust and confidence. This study aimed to reveal which issues divide different stakeholders in an attempt to determine the rights and/or obligations held on human biological materials (HBM) and data. METHODS Twenty-eight informants in the Benelux and Scandinavia were interviewed in order to capture the perspectives of experts and stakeholders in relation to the rights and obligations held by custodians and applicants with respect to access to HBM and data. RESULTS There was no consensus among the informants on whether the custodian of a biobank should decide upon the scientific merits and the utility of an access request. Nearly all informants agreed that a new request or an amendment to the initial request has to be submitted when an applicant wants to use leftover HBM in a new or follow-up project. Several informants felt that it might be justified to charge higher access fees to external or industrial applicants that did not contribute (directly or indirectly) to the collection of HBM and data. Most informants agreed that a custodian of a biobank could request the sharing and return of research results. It was furthermore argued that some of the benefits of research projects should be fed back into biobanks. CONCLUSIONS The interviews revealed a rather complex web of rights and obligations allocated to the custodian and the applicant in relation to access to HBM and data stored in biobanks. Some rights and obligations are negotiated on a case-by-case basis, while others are stipulated in access arrangements. We did find a consensus on the attribution of certain general rights to the custodians and the applicant.
Collapse
Affiliation(s)
- Michiel Verlinden
- Clinical Pharmacology and Pharmacotherapy, KU Leuven, Leuven, Belgium.
| | - Herman Nys
- Interfaculty Centre for Biomedical Ethics and Law, KU Leuven, Leuven, Belgium.
| | - Nadine Ectors
- AC Biobanking, UZ Leuven, Leuven, Belgium.
- Translational Cell & Tissue Research, KU Leuven, Leuven, Belgium.
| | - Isabelle Huys
- Clinical Pharmacology and Pharmacotherapy, KU Leuven, Leuven, Belgium.
- Centre for Intellectual Property Rights, KU Leuven, Leuven, Belgium.
| |
Collapse
|
14
|
Verlinden M, Nys H, Ectors N, Huys I. Access to biobanks: harmonization across biobank initiatives. Biopreserv Biobank 2015; 12:415-22. [PMID: 25496154 DOI: 10.1089/bio.2014.0034] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022] Open
Abstract
PURPOSE The current study investigates whether access arrangements relevant for biobanking contain clear information on key access conditions. It furthermore assesses the extent to which these access conditions are harmonized across biobank initiatives. METHODS A comparative analysis was conducted of access arrangements developed by 26 organizations, 36 biobank networks, and 20 biobanks worldwide. RESULTS The study demonstrates a lack of clear information on 21 key access conditions relevant for biobanking. Furthermore, it confirms that the harmonization across biobank initiatives is limited. CONCLUSION Many biobank initiatives need to be more transparent on how they apply the studied access conditions.
Collapse
|
15
|
Dove ES. Biobanks, Data Sharing, and the Drive for a Global Privacy Governance Framework. THE JOURNAL OF LAW, MEDICINE & ETHICS : A JOURNAL OF THE AMERICAN SOCIETY OF LAW, MEDICINE & ETHICS 2015; 43:675-689. [PMID: 26711409 DOI: 10.1111/jlme.12311] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]
Abstract
Biobanks are a key emerging biomedical research infrastructure. They manifest the turn towards greater global sharing of genomic and health-related data, which is considered by many to be an ethical and scientific imperative. Our collective interests lie in improving the health and welfare of individuals, communities, and populations; improving health and welfare requires access to, and use of, widely dispersed quality data. But sharing these individual and familial data requires in turn that due thought be given to the ethical and legal interests at stake. Most critically, data sharing must occur in an environment whereby privacy interests are safeguarded throughout the lifecycle of biobank initiatives, and regardless of the locations where the data are stored, to which they are sent, and where they are ultimately processed. In this article, I outline the complex dimensions of data privacy regulation that challenge data sharing within the biobanking context. I discuss how harmonization may be a remedy for the gaps and marked differences of approach in data privacy regulation. Finally, I encourage the development of foundational responsible data sharing principles set within an overarching governance framework that provides assurance that reasonable expectations of privacy will be met.
Collapse
Affiliation(s)
- Edward S Dove
- Ph.D. candidate in the School of Law at the University of Edinburgh. Previously, he was an Academic Associate at the Centre of Genomics and Policy at McGill University in Montreal. He received his LL.M. degree from Columbia University
| |
Collapse
|
16
|
Kosseim P, Dove ES, Baggaley C, Meslin EM, Cate FH, Kaye J, Harris JR, Knoppers BM. Building a data sharing model for global genomic research. Genome Biol 2014; 15:430. [PMID: 25221857 PMCID: PMC4282015 DOI: 10.1186/s13059-014-0430-2] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023] Open
Abstract
Data sharing models designed to facilitate global business provide insights for improving transborder genomic data sharing. We argue that a flexible, externally endorsed, multilateral arrangement, combined with an objective third-party assurance mechanism, can effectively balance privacy with the need to share genomic data globally.
Collapse
Affiliation(s)
- Patricia Kosseim
- />Office of the Privacy Commissioner of Canada, Ottawa, Ontario K1A 1H3 Canada
| | - Edward S Dove
- />Centre of Genomics and Policy, McGill University, Montreal, Quebec H3A 0G1 Canada
| | - Carman Baggaley
- />Office of the Privacy Commissioner of Canada, Ottawa, Ontario K1A 1H3 Canada
| | - Eric M Meslin
- />IU Center for Bioethics, Indiana University, Indianapolis, IN 46202 USA
- />Center for Law, Ethics, and Applied Research in Health Information, Bloomington, IN 47408 USA
| | - Fred H Cate
- />Center for Law, Ethics, and Applied Research in Health Information, Bloomington, IN 47408 USA
- />Maurer School of Law, Indiana University, Bloomington, IN 47405 USA
| | - Jane Kaye
- />HeLEX-Centre for Health, Law and Emerging Technologies, University of Oxford, Old Road Campus, Oxford, OX3 7LF UK
| | - Jennifer R Harris
- />Division of Epidemiology, Department of Genes and Environment, Norwegian Institute of Public Health, PO Box 4404, Nydalen, Oslo 0403 Norway
| | - Bartha M Knoppers
- />Centre of Genomics and Policy, McGill University, Montreal, Quebec H3A 0G1 Canada
| |
Collapse
|